Louisiana Administrative Code
Title 46 - PROFESSIONAL AND OCCUPATIONAL STANDARDS
Part XLV - Medical Professions
Subpart 3 - Practice
Chapter 69 - Prescription, Dispensation, and Administration of Medications
Subchapter A - Medications Used in the Treatment of Obesity
Section XLV-6903 - Definitions
Current through Register Vol. 50, No. 9, September 20, 2024
A. As used in this Subchapter, the following terms shall have the meanings specified.
Anorectic- a drug, medication, or substance used or intended for use as an appetite suppressant.
Schedule II Controlled Substance- any substance so classified under and pursuant to regulations of the Drug Enforcement Administration (DEA), U.S. Department of Justice, 21 CFR §1308 . 12, or any substance which may hereafter be so classified by amendment or supplementation of such regulation.
Schedule III Anorectic- benzphetamine, phendimetrazine, and any other substance now or hereafter classified as a Schedule III controlled substance under and pursuant to Federal DEA regulations, 21 CFR §1308 . 13, and which is indicated for use in the treatment of exogenous obesity by express approval of the U.S. Food and Drug Administration (FDA).
Schedule IV Anorectic- fenfluramine, dexfenfluramine, phentermine, diethylpropion, mazindol, and any other substance now or hereafter classified as a Schedule IV controlled substance under and pursuant to federal DEA regulations, 21 CFR § 1308.14 and which is indicated for use in the treatment of exogenous obesity by express approval of the FDA.
AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1270(A)(1), 37:1270(B)(6), and 37:1285(B).
